Brimonidine ophthalmic Alternatives Compared
| Brimonidine ophthalmic | Lumify (brimonidine) | Fluorometholone ophthalmic |
|
|---|
| Brimonidine ophthalmic | Lumify (brimonidine) | Fluorometholone ophthalmic |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription and OTC
Prescribed for Glaucoma - Open Angle, Intraocular Hypertension, Eye Redness. Brimonidine ophthalmic may also be used for purposes not listed in this medication guide. |
Over-the-counter
Prescribed for Eye Redness. Lumify may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Eyelash Hypotrichosis, Steroid Responsive Inflammatory Conditions, Eye Redness/Itching, Allergies, Eye Redness. Fluorometholone ophthalmic may also be used for purposes not listed in... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Brimonidine ophthalmic | More about Lumify (brimonidine) | More about Fluorometholone ophthalmic | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Brimonidine ophthalmic has an average rating of 3.4 out of 10 from a total of 192 ratings on Drugs.com. 21% of reviewers reported a positive effect, while 71% reported a negative effect. |
Lumify has an average rating of 3.2 out of 10 from a total of 174 ratings on Drugs.com. 19% of reviewers reported a positive effect, while 73% reported a negative effect. |
Fluorometholone ophthalmic has an average rating of 6.3 out of 10 from a total of 11 ratings on Drugs.com. 45% of reviewers reported a positive effect, while 27% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Brimonidine ophthalmic side effects |
View all Lumify side effects |
|||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic approved |
Lower cost generic |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Brimonidine ophthalmic prices |
View all Lumify prices |
View all Fluorometholone ophthalmic prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Alphagan P, Lumify, Lumify Preservative Free, Qoliana | Other brimonidine brands include: Alphagan P, Lumify Preservative Free, Qoliana | Eflone, Flarex, FML, FML Forte Liquifilm, FML Liquifilm, FML S.O.P. | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 367 drugs are known to interact with Brimonidine ophthalmic:
|
A total of 367 drugs are known to interact with Lumify:
|
A total of 42 drugs are known to interact with Fluorometholone ophthalmic:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
N/A |
December 22, 2017 |
N/A |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.